Adamis Pharmaceuticals Corporation

Good afternoon ladies and gentlemen and welcome to the Adamis Pharmaceuticals third quarter 2022 financial results conference call. At this time all lines are in a listen-only mode. If at any time during this call you require immediate assistance please press star zero for the operator. This call is being recorded on Monday November 14th 2022. I would now like to turn the conference over to Robert Robert Houle with ICR Westwick. Please go ahead.

Thank you, operator. Welcome to the Atomos Pharmaceuticals third quarter 2022 financial results and corporate update conference call. Thank you for joining us today for the update. Joining me on the call will be members of the Atomos executive team, including Chief Executive Officer David Margulio and Chief Financial Officer David Benedicto. They will share with us their various Atomos updates. Our format for this call will consist of prepared remarks from management, and following that, we will have a Q&A session. This call is being webcast and will be available for replay in the Investors section of our website, atomospharmaceuticals.com. In today's call, we will make certain forward-looking statements regarding our business based on current expectations and current information. These statements speak only as of today, and except as required by law, we do not assume any duty to update in the future any forward-looking statement made today. Of course, any forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements that we make today. Additional information concerning factors that could affect our business and financial results is included in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission and in other subsequent filings that we make with the SEC. These are available on the SEC's website. Now, please let me hand the call over to David Margulio, CEO of Atomos.

Thank you, Robert. I appreciate all of you for tuning in today for our third quarter update. After our clinical trial, examining the effects of Temple and COVID-19 treatment failed to achieve its primary endpoint. We paused and now have halted further development of Temple beginning at the end of September. In early October, we announced we had initiated a process to explore strategic and financing alternatives for the company. Those alternatives include partnering or outright sale of one or both of our commercial products, Simjepi and Zimhy, or the sale, merger, or reverse merger of the company. All of these options would have the objective of maximizing shareholder value. The company hired our longtime investment bank, Raymond James, as strategic advisor to assist and evaluate potential alternatives. We are presently actively involved in communications with third parties regarding which regarding this process, which could result in one or more possible transactions. While engaged in the process, we have implemented significant and successful expense reduction measures, including stopping all development programs and reducing employee headcount to just those individuals directly involved in either the manufacturing of our commercial products, maintaining regulatory compliance, or supporting the strategic process. These measures were necessary to preserve the company's limited cash while determining our path forward. Over the last few months, we've weathered a near perfect storm of both micro and macro events, which have severely limited the company's ability to operate. However, I'm confident that this process we began in October will conclude with one or more good options that will enable us to reset our strategy and place the company on a path to increasing shareholder value. While there can be no assurance that this process will result in a transaction and we have not established a schedule for completion of the review process, I expect that in the coming weeks we will have a better sense of where this process is likely to head. But until the company enters into a definitive agreement or otherwise determines that our disclosure is necessary or appropriate, we will not expect to disclose or provide updates concerning developments related to the process or the companies engaged in the process. I'd now like to turn it over to our CFO, David Benedicto, to provide a brief update on our recently filed third quarter financial results.